1. Home
  2. GNLX vs TIL Comparison

GNLX vs TIL Comparison

Compare GNLX & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.69

Market Cap

133.0M

Sector

Health Care

ML Signal

HOLD

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

N/A

Current Price

$7.39

Market Cap

48.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNLX
TIL
Founded
2001
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.0M
48.4M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
GNLX
TIL
Price
$2.69
$7.39
Analyst Decision
Strong Buy
Buy
Analyst Count
4
3
Target Price
$17.25
$125.00
AVG Volume (30 Days)
308.1K
6.4K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
9.47
6.06
EPS
N/A
N/A
Revenue
$8,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.29
$5.67
52 Week High
$8.54
$33.83

Technical Indicators

Market Signals
Indicator
GNLX
TIL
Relative Strength Index (RSI) 46.95 N/A
Support Level $2.39 N/A
Resistance Level $3.02 N/A
Average True Range (ATR) 0.21 0.00
MACD 0.00 0.00
Stochastic Oscillator 36.21 0.00

Price Performance

Historical Comparison
GNLX
TIL

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: